Form literature reviewing it turned out that Aprepitant didn't have a significant antiviral activity , another in-vitro study of Aprepitant as anti-HIV concluded that Aprepitant have low but reproducible anti-HIV activity, giving the fact that it might have some antiviral activity and it's safety make it a hard to dismiss candidate for COVID-19, there have been no studies of Aprepitant in COVID-19 not even in vitro. montelukast : Some research suggested possible antiviral activity of montelukast against Herpes Simplex Virus type-1 and Human Adeno Virus even though they are not related to SARS-CoV 2.